https://syndaxmedical.com/congress-presentation/a-phase-3-study-of-revumenib-plus-venetoclax-azacitidine-in-adults-with-newly-diagnosed-npm1-mutated-or-kmt2a-rearranged-acute-myeloid-leukemia-ineligible-for-intensive-chemotherapy-evolve-2-ho177-am/ 2026-06-04T21:17:10+00:00 https://syndaxmedical.com/congress-presentation/a-phase-3-study-of-revumenib-in-combination-with-intensive-chemotherapy-in-patients-with-newly-diagnosed-npm1-mutated-acute-myeloid-leukemia-reveal-nd-npm1-trial-in-progress/ 2026-06-04T21:17:35+00:00 https://syndaxmedical.com/congress-presentation/a-phase-3-study-of-revumenib-in-combination-with-intensive-chemotherapy-in-patients-with-newly-diagnosed-npm1-mutated-acute-myeloid-leukemia-reveal-nd-npm1-trial-in-progress-2/ 2026-06-04T21:17:47+00:00 https://syndaxmedical.com/congress-presentation/revumenib-venetoclax-azacitidine-in-adults-with-newly-diagnosed-npm1m-or-kmt2ar-acute-leukemia-ineligible-for-intensive-chemotherapy-evolve-2-ho177-amlsg35-24-act-hov-aml-002-trial-in-progress/ 2026-06-04T21:18:54+00:00 https://syndaxmedical.com/congress-presentation/revumenib-as-maintenance-for-aml-following-allogeneic-stem-cell-transplantation/ 2026-06-04T21:19:10+00:00 https://syndaxmedical.com/congress-presentation/pharmacokinetic-pk-assessment-of-revumenib-in-patients-with-relapsed-refractory-r-r-acute-leukemias-harboring-a-kmt2a-rearrangement-kmt2ar-or-npm1-mutation-npm1m-impact-of-food-and-concomitan/ 2026-06-04T21:20:02+00:00 https://syndaxmedical.com/congress-presentation/pharmacokinetic-assessment-of-revumenib-in-patients-with-relapsed-refractory-acute-leukemias-harboring-a-kmt2a-rearrangement-or-npm1-mutation-impact-of-food-and-concomitant-medications/ 2026-06-11T09:02:26+00:00 https://syndaxmedical.com/congress-presentation/clinical-activity-of-revumenib-in-patients-with-relapsed-refractory-nup98-rearranged-acute-leukemias/ 2026-06-11T09:03:05+00:00 https://syndaxmedical.com/congress-presentation/revumenib-in-the-real-world-interim-findings-from-the-roar-study-in-relapsed-refractory-acute-leukemia/ 2026-06-11T09:03:10+00:00 https://syndaxmedical.com/congress-presentation/a-phase-1-2-study-of-the-menin-inhibitor-revumenib-with-the-celmod-mezigdomide-in-relapsed-refractory-kmt2a-rearanged-npm1-mutant-and-nup98-rearranged-acute-leukemias/ 2026-06-11T09:03:13+00:00 https://syndaxmedical.com/congress-presentation/efficacy-of-revumenib-in-acute-myeloid-leukemia-harboring-npm1-mutated-co-mutations-post-hoc-analysis-of-augment-101/ 2026-06-11T09:03:16+00:00 https://syndaxmedical.com/congress-presentation/revumenib-therapy-post-hematopoietic-stem-cell-transplant-for-patients-with-relapsed-refractory-kmt2ar-npm1m-and-nup98r-acute-myeloid-leukemia-post-hoc-analysis-of-outcomes-from-augment-101/ 2026-06-11T09:03:19+00:00 https://syndaxmedical.com/congress-presentation/long-term-follow-up-of-pediatric-young-adult-patients-with-relapsed-refractory-kmt2ar-acute-leukemia-treated-with-revumenib-in-augment-101/ 2026-06-11T09:03:22+00:00 https://syndaxmedical.com/congress-presentation/revumenib-intensive-chemotherapy-for-newly-diagnosed-acute-myeloid-leukemia-harboring-genetic-alterations-in-kmt2a-npm1-or-nup98-updated-phase-1-results-from-sndx-5613-0708/ 2026-06-11T09:03:25+00:00 https://syndaxmedical.com/congress-presentation/revumenib-as-maintenance-for-aml-following-allogeneic-stem-cell-transplantation-2/ 2026-06-11T09:03:30+00:00 https://syndaxmedical.com/congress-presentation/phase-1-2-study-of-the-all-oral-combination-of-revumenib-sndx-5613-with-decitabine-cedazuridine-astx727-and-venetoclax-save-in-relapsed-refractory-aml/ 2026-06-11T09:03:39+00:00